Metavia Inc

This proposal asks shareholders to authorize the Board to amend the Certificate of Incorporation to permit a reverse split of common stock at a ratio between 1-for-5 and 1-for-22, with the Board given discretion to select the precise ratio and timing within one year of shareholder approval or to abandon the split if deemed not in shareholders’ best interests. Management seeks this authorization primarily to raise the per‑share market price to improve compliance with Nasdaq’s minimum bid price requirement and to broaden the potential investor base, particularly institutional investors that avoid low‑priced stocks. The filing explains the mechanics — the split would reduce outstanding shares proportionately (subject to fractional‑share cash-out treatment), leave authorized shares unchanged, and adjust exercise prices and share amounts for options, warrants and RSUs. The Board argues the split could enhance liquidity and reduce certain transaction and processing frictions associated with low‑priced stock, but it discloses that it cannot guarantee proportional or sustained price appreciation and that the total market capitalization may decline post‑split. The company acknowledges specific risks: increased odd‑lot holdings, potential for accelerated delisting consequences under recent Nasdaq rules if further splits are needed, and that the reverse split increases the pool of authorized but unissued shares which could enable future dilution. The Board retains discretion over whether to effect the split and at which ratio, enabling it to act based on market conditions; this flexibility helps management implement a tailored response but also concentrates execution authority in the Board. For investors evaluating the tradeoff, the key considerations are the company’s near‑term ability to meet Nasdaq listing standards without a split, the potential signaling effect of a split, the dilution dynamics from unchanged authorized shares, and the operational consequences for small holders who may be cashed out of fractional positions. Overall, the proposal is a management tool to address listing and marketability concerns but contains material risks that could affect liquidity, shareholder composition, and future corporate actions.

This management proposal requests shareholder approval to amend the Company’s 2022 Equity Incentive Plan to add 200,000 shares to the aggregate share reserve, a modest top‑up to support ongoing equity compensation grants. Management argues the increase is needed to continue granting stock‑based awards to recruit, retain and motivate employees, consultants, officers and non‑employee directors in a competitive life‑sciences labor market and that equity awards align employee incentives with shareholder outcomes. The amendment leaves the plan’s existing “evergreen” provision intact (an automatic annual increase equal to 10% of fully diluted shares through 2032) and would be followed by an S‑8 registration statement to register the additional shares if approved. The proposal is standard from a governance standpoint — increasing the reserve is dilutive to existing holders but customary for companies that rely on equity compensation; the filing discloses that insiders participate under the plan, creating potential conflicts that the compensation committee oversees. Important analytical considerations include the company’s current burn rate, remaining runway of outstanding awards, and whether the increment aligns with hiring and retention needs without excessive dilution. The Board’s recommendation reflects a judgment that the marginal increase is prudent to preserve recruiting flexibility and incentivize performance, but investors should weigh dilution against the expected retention and performance benefits and monitor future grant practices and disclosures. Approval would preserve the Company’s ability to issue equity in lieu of cash compensation and to structure incentive arrangements that support development milestones and commercialization objectives.

This proposal asks shareholders to grant the Board authority to adjourn and reconvene the Annual Meeting for up to 30 days (without changing the record date or providing additional notice except an announcement at the meeting) if there are insufficient votes to approve Proposals 3 or 4, enabling the company to solicit additional proxies. Management seeks this authorization as a practical procedural mechanism to maximize the likelihood that critical, non-routine proposals (the reverse split and equity plan amendment) can be approved without holding a new meeting or re-setting a record date. The adjournment power preserves existing proxy instructions so that previously-submitted proxies can be reflected at the reconvened meeting, reducing administrative burden and cost. From a governance perspective, the adjournment is a standard and non-substantive mechanism; it does not change the substance of any proposal nor confer additional substantive rights but can affect timing and the opportunity for further engagement with shareholders. Shareholders should note that the adjournment could be used to continue solicitation efforts after an initial vote failure, which benefits management’s ability to win approval but delays finality. The Board recommends the vote to ensure flexibility to achieve shareholder approval of Proposals 3 and 4, which the company deems important to its listing status and compensation program. Investors evaluating this item should treat it as a procedural convenience rather than a materially substantive vote, while monitoring any follow-up solicitations and communications during any adjournment period.